Treatment with finasteride and prostate cancer survival

Scandinavian Journal of Urology

Volumn 47, Issue 4, 2013, Pages 265-271

  Kjellman, Anders ^a   Friis, Søren ^b   Granath, Fredrik ^c   Gustafsson, Ove ^a   Sorensen, Henrik Tøft ^d   Akre, Olof ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^c KAROLINSKA INSTITUTE   (Sweden)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

5 reductase inhibitors; Dihydrotestosterone; Finasteride; Prognosis; Prostate cancer

Indexed keywords

FINASTERIDE;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; DENMARK; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; DENMARK; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FINASTERIDE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84880483854     PISSN: 21681805     EISSN: 21681813     Source Type: Journal    
DOI: 10.3109/00365599.2012.737366     Document Type: Article

References (21)

1. Imamoto T, Suzuki H, Utsumi T, Endo T, Takano M, Yano M, et al. Association between serum sex hormone levels and prostate cancer: Effect of prostate cancer on serum testosterone levels. Future Oncol 2009;5:1005-13.
2. Kjellman A, Akre O, Norming U, Tornblom M, Gustafsson O. Dihydrotestosterone levels and survival in screening-detected prostate cancer: A 15-yr follow-up study. Eur Urol 2008;53:106-11. (Pubitemid 350166707)
3. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl JMed 2003;349: 215-24. (Pubitemid 36859473)
4. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D, et al. Chemoprevention of prostate cancer in men at high risk: Rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol 2004;172:1314-17. (Pubitemid 39249705)
5. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362: 1192-202.
6. Murtola TJ, Tammela TL, Maattanen L, Ala-Opas M, Stenman UH, Auvinen A. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. Br J Cancer 2009;101:843-8.
7. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 2006;53:441-9. (Pubitemid 44816920)
8. Ehrenstein V, Antonsen S, Pedersen L. Existing data sources for clinical epidemiology: Aarhus University Prescription Database. Clin Epidemiol 2010;2:273-9.
9. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997;44:445-8. (Pubitemid 27382061)
10. World Health Organization. ATC classification index with DDDs. Geneva: WHO; 2003.
11. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry -history, content, quality and use. Dan Med Bull 1997;44:535-9.
12. Juel K. Registration of cause of death in Denmark. Ugeskr Laeger 1998;160:5019.
13. Mabeck CE, Wichmann B. Causes of death and death certificates. An evaluation of the diagnosis in 373 death certificates. Ugeskr Laeger 1980;142:257-61. (Pubitemid 10177396)
14. Asnaes S, Ostergaard K. Reliability of death certificates. An autopsy study. Ugeskr Laeger 1980;142:265-6.
15. Brasso K, Friis S, Juel K, Jorgensen T, Iversen P. Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: A population based registry study. J Urol 1999;161:524-8.
16. Benning CM, Kyprianou N. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor- independent action. Cancer Res 2002;62:597-602. (Pubitemid 34106437)
17. Harris AM, Warner BW, Wilson JM, Becker A, Rowland RG, Conner W, et al. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: An observational cohort study. J Urol 2007;178:2176-80. (Pubitemid 47538576)
18. Orsted DD, Bojesen SE, Nielsen SF, Nordestgaard BG. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: A nationwide cohort study of 3 009 258 men. Eur Urol 2011;60:691-8.
19. Jonler M, Eddy B, Poulsen J. Prostate-specific antigen testing in general practice: A survey among 325 general practitioners in Denmark. Scand J Urol Nephrol 2005;39:214-18. (Pubitemid 40979081)
20. Murtola TJ, Tammela TL, Maattanen L, Hakama M, Auvinen A. Prostate cancer risk among users of finasteride and alpha-blockers -a population based case-control study. Eur J Cancer 2007;43:775-81. (Pubitemid 46502907)
21. Lebdai S, Bigot P, Azzouzi AR. High-grade prostate cancer and finasteride. BJU Int 2010;105:456-9.